• 1
    Hoffmann H.M.R., Rabe J. (1985) Synthesis and biological activity of alfa-methylene-gamma-butyrolactones. Angew Chem Int Ed Engl;24:94110.
  • 2
    Zhang S., Won Y.K., Ong C.N., Shen H.M. (2005) Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents;5:239249.
  • 3
    Konishi T., Shimada Y., Nagao T., Okabe H., Konoshima T. (2002) Antiproliferative sesquiterpene lactones from the roots of Inula helenium. Biol Pharm Bull;25:13701372.
  • 4
    Won Y.K., Ong C.N., Shi X., Shen H.M. (2004) Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis;25:14491458.
  • 5
    Heilmann J., Wasescha M.R., Schmidt T.J. (2001) The influence of glutathione and cysteine levels on the cytotoxicity of helenanolide type sesquiterpene lactones against KB cells. Bioorg Med Chem;9:21892194.
  • 6
    Knight D.W. (1995) Feverfew: chemistry and biological activity. Nat Prod Rep;12:271276.
  • 7
    Zhang S., Ong C.N., Shen H.M. (2004) Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett;208:143153.
  • 8
    Nakagawa Y., Iinuma M., Matsuura N., Yi K., Naoi M., Nakayama T., Nozawa Y., Akao Y. (2005) A potent apoptosis-inducing activity of a sesquiterpene lactone, arucanolide, in HL60 cells: a crucial role of apoptosis-inducing factor. J Pharmacol Sci;97:242252.
  • 9
    Rivero A., Quintana J., Eiroa J.L., Lopez M., Triana J., Bermejo J., Estévez F. (2003) Potent induction of apoptosis by germacranolide sesquiterpene lactones on human myeloid leukemia cells. Eur J Pharmacol;482:7784.
  • 10
    Dirsch V.M., Stuppner H., Vollmar A.M. (2001) Helenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of Bcl-x(L) or Bcl-2. Cancer Res;61:58175823.
  • 11
    Wen J., You K.R., Lee S.Y., Song C.H., Kim D.G. (2002) Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem;277:3895438964.
  • 12
    Liu J.W., Cai M.X., Xin Y., Wu Q.S., Ma J., Yang P., Xie H.Y., Huang D.S. (2010) Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp Clin Cancer Res;29:108.
  • 13
    Mendonca M.S., Chin-Sinex H., Gomez-Millan J., Datzman N., Hardacre M., Comerford K., Nakshatri H., Nye M., Benjamin L., Mehta S., Patino F., Sweeney C. (2007) Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair. Radiat Res;168:689697.
  • 14
    Hehner S.P., Hofmann T.G., Droge W., Schmitz M.L. (1999) The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol;163:56175623.
  • 15
    Saadane A., Masters S., DiDonato J., Li J., Berger M. (2007) Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol;36:728736.
  • 16
    Pajak B., Gajkowska B., Orzechowski A. (2008) Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol;46:129135.
  • 17
    Janecki T., Wasek T., Rozalski M., Krajewska U., Studzian K., Janecka A. (2006) 4-Methylideneisoxazolidin-5-ones – a new class of alpha-methylidene-gamma-lactones with high cytostatic activity. Bioorg Med Chem Lett;16:14301433.
  • 18
    Rozalski M., Krajewska U., Panczyk M., Mirowski M., Rozalska B., Wasek T., Janecki T. (2007) Synthesis and biological evaluation of 4-methylideneisoxazolidin-5-ones – a new class of highly cytotoxic alpha-methylidene-gamma-lactones. Eur J Med Chem;42:248255.
  • 19
    Krawczyk H., Albrecht Ł. (2005) Knoevenagel reaction of diethylphosphonoacetic acid: a facile route to diethyl (E)-2-arylvinylphosphonates. Synthesis;2005:28872896.
  • 20
    Berridge M.V., Tan A.S. (1993) Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electrontransport in MTT reduction. Arch Biochem Biophys;303:474482.
  • 21
    Liu Y., Peterson D.A., Kimura H., Schubert D. (1997) Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem;69:581593.
  • 22
    Rodriguez L.G., Wu X., Guan J.L. (2005) Wound-healing assay. Methods Mol Biol;294:2329.
  • 23
    Yin Y., Chen X., Shu Y. (2009) Gene expression of the invasive phenotype of TNF-a-treated MCF-7 cells. Biomed Pharmacother;63:421428.
  • 24
    Hrabec E., Strek M., Nowak D., Greger J., Suwalski M., Hrabec Z. (2002) Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J Cancer Res Clin Oncol;128:197204.
  • 25
    Kitson R.R.A., Millemaggi A., Taylor R.J.K. (2009) The renaissance of α-methylene-γ-butyrolactones: new synthetic approaches. Angew Chem Int Ed;48:94269451.
  • 26
    Albrecht A., Albrecht Ł. , Janecki T. (2011) Recent advances in the synthesis of α-alkylidene-δ-lactones, α-alkylidene-γ-lactams and α-alkylidene-δ-lactams. Eur J Org Chem;2011:27472766.
  • 27
    Steeg P.S., Theodorescu D. (2008) Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol;5:206219.
  • 28
    Geiger T.R., Peeper D.S. (2009) Metastasis mechanisms. Biochim Biophys Acta;1796:293308.
  • 29
    Engbring J.A., Kleinman H.K. (2003) The basement membrane matrix in malignancy. J Pathol;200:465470.
  • 30
    Widel M.S., Widel M. (2006) Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer. Postepy Hig Med Dosw (Online);60:453470.
  • 31
    Shariftabrizi A., Nifli A.P., Ansari M., Saadat F., Ebrahimkhani M.R., Alizadeh N., Nasseh A., Alexaki V.I., Dehpour A.R., Castanas E., Khorramizadeh M.R. (2006) Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine. Eur J Pharmacol;530:3339.
  • 32
    Das S., Banerji A., Frei E., Chatterjee A. (2008) Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci;82:467476.
  • 33
    Duffy M.J. (2004) The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des;10:3949.
  • 34
    Duffy M.J., Duggan C. (2004) The urokinase plasminogen activator system: a rich source of tumour markers for the individualized management of patients with cancer. Clin Biochem;37:541548.